drugset / Trial / NCT02240433
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
Timeline
- Start
- 2014-11-12
- Primary completion
- 2017-07-19
- Completion
- 2019-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galunisertib | Small molecule | — | Oral |
| Background | Sorafenib | Small molecule | — | Oral |